ECSP22040362A - Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x - Google Patents

Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x

Info

Publication number
ECSP22040362A
ECSP22040362A ECSENADI202240362A ECDI202240362A ECSP22040362A EC SP22040362 A ECSP22040362 A EC SP22040362A EC SENADI202240362 A ECSENADI202240362 A EC SENADI202240362A EC DI202240362 A ECDI202240362 A EC DI202240362A EC SP22040362 A ECSP22040362 A EC SP22040362A
Authority
EC
Ecuador
Prior art keywords
liver
derivatives
receptor agonists
compound
formula
Prior art date
Application number
ECSENADI202240362A
Other languages
English (en)
Inventor
Jeffrey Smith
Kathryn Taylor Linkens
Fupeng Ma
Zhihong Huang
Declan Hardy
Valentina Molteni
Catherine Fooks Solovay
Alec Nathanson Flyer
Duncan Shaw
Kelly D Boss
Jon Christopher Loren
Yi Fan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22040362A publication Critical patent/ECSP22040362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan aquí compuestos y composiciones farmacéuticas útiles para el tratamiento de la disfunción de la glándula de Meibomio (MGD), que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de un compuesto de Fórmula (I) o un compuesto de Fórmula (I’), o una composición farmacéutica descripta en la presente memoria.
ECSENADI202240362A 2019-11-25 2022-05-19 Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x ECSP22040362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US202063106293P 2020-10-27 2020-10-27

Publications (1)

Publication Number Publication Date
ECSP22040362A true ECSP22040362A (es) 2022-06-30

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202240362A ECSP22040362A (es) 2019-11-25 2022-05-19 Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x

Country Status (19)

Country Link
US (2) US11427586B2 (es)
EP (1) EP4065228A1 (es)
JP (1) JP2023503320A (es)
KR (1) KR20220106778A (es)
CN (1) CN114746149A (es)
AU (1) AU2020394597B2 (es)
BR (1) BR112022009942A2 (es)
CA (1) CA3157657A1 (es)
CL (1) CL2022001323A1 (es)
CO (1) CO2022006645A2 (es)
CR (1) CR20220227A (es)
EC (1) ECSP22040362A (es)
IL (1) IL291958A (es)
JO (1) JOP20220124A1 (es)
MX (1) MX2022006151A (es)
PE (1) PE20221785A1 (es)
TW (1) TW202132289A (es)
UY (1) UY38964A (es)
WO (1) WO2021105857A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243907A1 (en) * 2021-05-20 2022-11-24 Novartis Ag Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR20240059836A (ko) 2022-10-28 2024-05-08 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2015187840A2 (en) 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
JP2022514257A (ja) 2018-12-13 2022-02-10 アイノス，インコーポレイテッド ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト

Also Published As

Publication number Publication date
AU2020394597A1 (en) 2022-06-02
KR20220106778A (ko) 2022-07-29
EP4065228A1 (en) 2022-10-05
IL291958A (en) 2022-06-01
US11427586B2 (en) 2022-08-30
PE20221785A1 (es) 2022-11-22
CN114746149A (zh) 2022-07-12
AU2020394597B2 (en) 2024-03-14
JP2023503320A (ja) 2023-01-27
TW202132289A (zh) 2021-09-01
CR20220227A (es) 2022-06-15
UY38964A (es) 2021-06-30
CL2022001323A1 (es) 2023-03-24
WO2021105857A1 (en) 2021-06-03
BR112022009942A2 (pt) 2022-08-09
MX2022006151A (es) 2022-08-02
US20220064164A1 (en) 2022-03-03
CA3157657A1 (en) 2021-06-03
JOP20220124A1 (ar) 2023-01-30
CO2022006645A2 (es) 2022-05-31
US20220340573A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
AR127470A1 (es) Inhibidores de lrrk2
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
MX2019012522A (es) Compuestos y metodos terapeuticos.
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
CU20130004A7 (es) Agentes terapéuticos 976
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas